Skip to main content

CASI Pharmaceuticals, Inc.

CASIF
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001962738

No open-market purchases or sales by CASI Pharmaceuticals, Inc. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $17 in total; no superinvestor holds it.

Q2 2024 vs. Q1 2024

How the institutions holding CASI Pharmaceuticals, Inc. changed between Q1 2024 and Q2 2024.

All holders in Q2 2024All holders in Q1 2024

13F holders of CASIF: Q1 2024 compared with Q2 2024
MeasureQ1 2024Q2 2024Change
Holders2023+3
Shares252.0K352.2K+100.2K (+39.7%)
Value$909.6K$1.94M+$1.03M (+112.9%)

New holders (7)

Institutions that held CASI Pharmaceuticals, Inc. at the end of Q2 2024 but not at the end of Q1 2024.

Institutions new to CASIF in Q2 2024
InstitutionSharesValue% of portfolio
VR Adviser, LLC111,686$614.3K0.04%
UBS Group AG11,321$62.3K0.00%
ADAR1 Capital Management, LLC8,240$45.3K0.01%
Royal Bank of Canada6,900$38.0K0.00%
Qube Research & Technologies Ltd100$5500.00%
Trust Co of Vermont10$550.00%
Advisor Group Holdings, Inc.8$440.00%

Sold out (4)

Institutions that held CASI Pharmaceuticals, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.

Institutions that sold out of CASIF in Q2 2024
InstitutionShares, Q1 2024Value, Q1 2024
FMR LLC500$1.80K
TD Waterhouse Canada Inc.300$1.03K
IFP Advisors, Inc40$144
Mendota Financial Group, LLC20$73